IFP Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

IFP Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.5K	Buy	2,000 +1,052	+111%	+$25.1K	﹤0.01%	2251
2025 Q4	$22.1K	Buy	948 +945	+31,500%	+$21.1K	﹤0.01%	2682
2025 Q3	$59	Sell	3 -101	-97%	-$2.08K	﹤0.01%	4631
2025 Q2	$2.26K	Buy	104 +81	+352%	+$1.91K	﹤0.01%	3842
2025 Q1	$558	Hold	23	–	–	﹤0.01%	3438
2024 Q4	$480	Buy	+23	New	+$494	﹤0.01%	3427
2023 Q3	–	Sell	-670	Closed	-$9K	–	3344
2023 Q2	$9K	Buy	670 +170	+34%	+$2.45K	﹤0.01%	2336
2023 Q1	$1.81K	Sell	500 -1,523	-75%	-$25.1K	﹤0.01%	2927
2022 Q4	$12K	Sell	2,023 -376	-16%	-$5.79K	﹤0.01%	3253
2022 Q3	$9K	Hold	2,399	–	–	﹤0.01%	3698
2022 Q2	$9K	Hold	2,399	–	–	﹤0.01%	3454
2022 Q1	$9K	Buy	+2,399	New	+$17K	﹤0.01%	3454
2019 Q4	–	Sell	-1,324	Closed	-$6.19K	–	2874
2019 Q3	$7K	Buy	+1,324	New	+$7.05K	﹤0.01%	2209
2017 Q4	–	Sell	-1,000	Closed	-$3K	–	3841
2017 Q3	$3K	Hold	1,000	–	–	﹤0.01%	3597
2017 Q2	$3K	Hold	1,000	–	–	﹤0.01%	3591
2017 Q1	$2K	Hold	1,000	–	–	﹤0.01%	3632
2016 Q4	$1K	Hold	1,000	–	–	﹤0.01%	3759
2016 Q3	$1K	Hold	1,000	–	–	﹤0.01%	3699
2016 Q2	$1K	Buy	+1,000	New	+$806	﹤0.01%	3591

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

IFP Advisors's CPRX Position: Q1 2026 in Review

IFP Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 111% in Q1 2026, buying an estimated $25.1K and bringing the position to 2,000 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

IFP Advisors first reported a position in CPRX in Q2 2016 and has held it in 19 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

IFP Advisors held 2,000 shares of Catalyst Pharmaceutical worth $49.5K as of Q1 2026.
IFP Advisors bought 1,052 Catalyst Pharmaceutical shares in Q1 2026, an estimated $25.1K.
Catalyst Pharmaceutical made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #2251 holding.
IFP Advisors first reported a position in Catalyst Pharmaceutical in Q2 2016 and has held it in 19 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.